[Endothelial dysfunction and metabolic effects of nitric oxide in human].
Kolesnichenko
O Iu
OIu
Filatova
L M
LM
Krivitsina
Z A
ZA
Voronkov
Iu I
IuI
D001161:Arteriosclerosis / Q000378:metabolism / Q000517:prevention & control; D001578:Benzopyrans / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D004983:Ethanolamines / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D008875:Middle Aged; D000068577:Nebivolol; D009569:Nitric Oxide / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013927:Thrombosis / Q000378:metabolism / Q000517:prevention & control
D001578:Benzopyrans; D004983:Ethanolamines; D008055:Lipids; D010975:Platelet Aggregation Inhibitors; D000068577:Nebivolol; D009569:Nitric Oxide